Business Wire

DEENOVA

2.8.2021 08:02:50 CEST | Business Wire | Press release

Share
Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract

Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova 's competitors in United Kingdom and the United States of America.

Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust , said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospitals. This programme will ensure the right medicines are in the right place at the right time and will undoubtedly improve care for our patients.”

Giorgio Pavesi , Managing Director of Deenova in Italy stated: “I am extremely proud of the teamwork and dedication exhibited by our employees and those of University Hospitals of Leicester NHS Trust , proving to the health care industry the patient safety and economic advantages of Deenova ´s unique Closed-Loop Medication Unit Dose management system and services, as evidenced by the report issued by the East Midlands Academic Health Science Network (AHSN) undertaking an 18 month evaluation of Deenova solutions. The published results included: 25% reduction in the consumption (and costs) of medicines; 40% reduction in the number of items held in the ward stock cupboard, 60% reduction in medicines wastage, and a reduction in missed doses due to medicine not available on wards from 10% to 1.2%, amongst other patient safety and economical benefits, leading to this award.”

Deenova plans to fulfill University Hospitals of Leicester NHS Trust ’s contract award with delivery, installation and full service/support for 3 All-in-1 and 1 Acced Packaging Robots, 56 All-in-1 Station Medication Dispensing Robots, and more than 100 All-in-1 Trolleys with secure bed-side verification.

East Midlands AHSN Commercial Director, Tim Robinson , said: “A key role of AHSNs is to help build collaboration across sectors, and in particular to connect commercial innovators with the heath and care organisations that could benefit from their innovations. With this in mind, we welcome the progress made in Leicester - this is a great example of how the NHS and commercial sector can work in partnership. As well as the potential to benefit patients and generate efficiencies, we also welcome the investment into the East Midlands and the jobs this partnership will create.”

Information

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova ’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and making the best use of staff time. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.

University Hospitals of Leicester NHS Trust : Every day at Leicester’s Hospitals we save lives, improve lives and usher in new life. We want to continue to improve everything that we do, so that we can achieve our vision: Caring at its best for every patient, every time. As one of the largest NHS Trusts in the country, our contribution goes beyond health; we are the largest employer in our region, we educate and train the staff of the future, push the boundaries of research and with our £1bn turnover are an economic engine for East Midlands and beyond. This is a particularly exciting time for Leicester’s Hospitals. We have been given £450m to reconfigure services and build new hospitals. This will include a new Children’s Hospital, Maternity Hospital, Treatment Centre and two new Intensive Care Units. For more information please visit: www.leicestershospitals.nhs.uk

The East Midlands Academic Health Science Network (EMAHSN) is one of 15 Academic Health Science Networks in England that operate as the innovation arm of the NHS. AHSNs bring together the NHS, universities, industry and social care to transform health and stimulate economic growth. In the East Midlands our current priorities focus on identifying and spreading innovations that respond to the COVID-19 pandemic and the recovery of services, along with priority themes including mental health, patient safety and optimising medicines. For more information please visit: www.emahsn.org.uk

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release

Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye